BRNS's Forward Dividend Yield % is not ranked *
in the Biotechnology industry.
Industry Median: 1.52 * Ranked among companies with meaningful Forward Dividend Yield % only.
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
Barinthus Biotherapeutics Forward Dividend Yield % Related Terms
BRNS vs VTGN, PSTV, PVCT: Forward Dividend Yield % Comparison
For the Biotechnology subindustry, Barinthus Biotherapeutics's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Barinthus Biotherapeutics Forward Dividend Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Barinthus Biotherapeutics's Forward Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Barinthus Biotherapeutics's Forward Dividend Yield % falls into.
What does a Forward Dividend Yield % of 0.00% mean?
Barinthus Biotherapeutics (BRNS) has a Forward Dividend Yield % of 0.00% as of Jun. 30, 2026. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Barinthus Biotherapeutics and its competitors. According to the industry distribution chart, Barinthus Biotherapeutics ranks #999999 out of 145 companies in the Biotechnology industry.
Is Barinthus Biotherapeutics' Forward Dividend Yield % too high?
Barinthus Biotherapeutics' current Forward Dividend Yield % is 0.00%. Based on the distribution chart, Barinthus Biotherapeutics ranks #999999 out of 145 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Barinthus Biotherapeutics has a GF Score™ of 52/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Barinthus Biotherapeutics' Forward Dividend Yield % compare to VTGN and PSTV?
According to the Biotechnology industry distribution chart, Barinthus Biotherapeutics ranks #999999 out of 145 companies for Forward Dividend Yield %. This places Barinthus Biotherapeutics in the lower half of its industry. The industry median Forward Dividend Yield % is 1.52. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward Dividend Yield % for a Biotechnology company?
The median Forward Dividend Yield % among Biotechnology companies is 1.52, based on 145 companies in the industry. Companies in the top quartile (top 25%) have a Forward Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Forward Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward Dividend Yield % mean?
A high Forward Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Barinthus Biotherapeutics and its competitors. For the Biotechnology industry, the median Forward Dividend Yield % is 1.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Barinthus Biotherapeutics's current Forward Dividend Yield % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Barinthus Biotherapeutics stock overvalued right now?
Based on GuruFocus' analysis, Barinthus Biotherapeutics (BRNS) is currently considered Possible Value Trap. The stock's GF Value™ is $1.12, compared to a current price of $0.66 — trading 41.1% below its estimated fair value. The current Forward Dividend Yield % is 0.00%. Barinthus Biotherapeutics' overall GF Score™ is 52/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward Dividend Yield % calculated?
Forward Dividend Yield % is calculated from a company's financial statements. For Barinthus Biotherapeutics (BRNS), the current Forward Dividend Yield % is 0.00% as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Barinthus Biotherapeutics (BRNS) Overvalued in 2026?
Based on GuruFocus' analysis, Barinthus Biotherapeutics stock appears to be undervalued.
The current stock price of $0.66 is trading 41.1% below its estimated GF Value™ of $1.12.
GuruFocus considers Barinthus Biotherapeutics to be Possible Value Trap.
Key valuation signals for BRNS:
Forward Dividend Yield %: 0.00%
GF Value™: $1.12 vs. price of $0.66 (41.1% below fair value)
No single metric tells the full story. See the BRNS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapeutic drug candidates for treating autoimmune and inflammatory diseases. The company is prioritizing the development of its proprietary SNAP-TI platform, designed to promote immune tolerance, with its lead candidate VTP-1000 targeting celiac disease. It is also developing VTP-300 for chronic hepatitis B using viral vector platform technologies, aimed at inducing disease-specific immune responses.
52GF Score
Get the complete analysis for BRNS
Forward Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BRNS has been successfully added to your 